Macrolides in critically ill patients with Middle East Respiratory Syndrome

Yaseen M Arabi, Ahmad M Deeb, Fahad Al-Hameed, Yasser Mandourah, Ghaleb A Almekhlafi, Anees A Sindi, Awad Al-Omari, Sarah Shalhoub, Ahmed Mady, Basem Alraddadi, Abdullah Almotairi, Kasim Al Khatib, Ahmed Abdulmomen, Ismael Qushmaq, Othman Solaiman, Abdulsalam M Al-Aithan, Rajaa Al-Raddadi, Ahmad Ragab, Abdulrahman Al Harthy, Ayman Kharaba, Jesna Jose, Tarek Dabbagh, Robert A Fowler, Hanan H Balkhy, Laura Merson, Frederick G Hayden, Saudi Critical Care Trials group, Yaseen M Arabi, Ahmad M Deeb, Fahad Al-Hameed, Yasser Mandourah, Ghaleb A Almekhlafi, Anees A Sindi, Awad Al-Omari, Sarah Shalhoub, Ahmed Mady, Basem Alraddadi, Abdullah Almotairi, Kasim Al Khatib, Ahmed Abdulmomen, Ismael Qushmaq, Othman Solaiman, Abdulsalam M Al-Aithan, Rajaa Al-Raddadi, Ahmad Ragab, Abdulrahman Al Harthy, Ayman Kharaba, Jesna Jose, Tarek Dabbagh, Robert A Fowler, Hanan H Balkhy, Laura Merson, Frederick G Hayden, Saudi Critical Care Trials group

Abstract

Objectives: Macrolides have been reported to be associated with improved outcomes in patients with viral pneumonia related to influenza and other viruses, possibly because of their immune-modulatory effects. Macrolides have frequently been used in patients with Middle East Respiratory Syndrome (MERS). This study investigated the association of macrolides with 90-day mortality and MERS coronavirus (CoV) RNA clearance in critically ill patients with MERS.

Methods: This retrospective analysis of a multicenter cohort database included 14 tertiary-care hospitals in five cities in Saudi Arabia. Multivariate logistic-regression analysis was used to determine the association of macrolide therapy with 90-day mortality, and the Cox-proportional hazard model to determine the association of macrolide therapy with MERS-CoV RNA clearance.

Results: Of 349 critically ill MERS patients, 136 (39%) received macrolide therapy. Azithromycin was most commonly used (97/136; 71.3%). Macrolide therapy was commonly started before the patient arrived in the intensive care unit (ICU) (51/136; 37.5%), or on day1 in ICU (53/136; 39%). On admission to ICU, the baseline characteristics of patients who received and did not receive macrolides were similar, including demographic data and sequential organ failure assessment score. However, patients who received macrolides were more likely to be admitted with community-acquired MERS (P=0.02). Macrolide therapy was not independently associated with a significant difference in 90-day mortality (adjusted odds ratio [OR]: 0.84; 95% confidence interval [CI] :0.47-1.51; P=0.56) or MERS-CoV RNA clearance (adjusted HR: 0.88; 95% CI:0.47-1.64; P=0.68).

Conclusions: These findings indicate that macrolide therapy is not associated with a reduction in 90-day mortality or improvement in MERS-CoV RNA clearance.

Keywords: Azithromycin; Critical care; Influenza; MERS-CoV; Macrolides; Pneumonia.

Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Time to initiation of macrolide therapy from ICU admission among critically ill patients with Middle East Respiratory Syndrome (MERS). Day 0 includes patients who were already on macrolides therapy before being admitted to ICU. There were 11 patients who recieved two macrolides at different times during the study period, and one patient with missing data regarding the date of macrolide therapy.

References

    1. Amsden G.W. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55(1):10–21.
    1. Arabi Y.M., Al-Omari A., Mandourah Y., Al-Hameed F., Sindi A.A., Alraddadi B. Critically ill patients with the middle east respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med. 2017;45(10):1683–1695.
    1. Beigelman A., Bacharier L.B., Baty J., Buller R., Mason S., Schechtman K.B. Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis? J Allergy Clin Immunol. 2015;136(4):1129–1131.
    1. Beigelman A., Mikols C.L., Gunsten S.P., Cannon C.L., Brody S.L., Walter M.J. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res. 2010;11:90.
    1. Bermejo-Martin J.F., Kelvin D.J., Eiros J.M., Castrodeza J., Ortiz de Lejarazu R. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries. 2009;3(3):159–161.
    1. Gielen V., Johnston S.L., Edwards M.R. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646–654.
    1. Higashi F., Kubo H., Yasuda H., Nukiwa T., Yamaya M. Additional treatment with clarithromycin reduces fever duration in patients with influenza. Respir Investig. 2014;52(5):302–309.
    1. Hung I.F.N., To K.K.W., Chan J.F.W., Cheng V.C.C., Liu K.S.H., Tam A. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017;151(5):1069–1080.
    1. ISARIC. The international severe acute respiratory and emerging infection consortium case report forms. Available from: . [Accessed 1 November 2018].
    1. Kakeya H., Seki M., Izumikawa K., Kosai K., Morinaga Y., Kurihara S. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One. 2014;9(3)
    1. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590–615.
    1. Kneyber M.C., van Woensel J.B., Uijtendaal E., Uiterwaal C.S., Kimpen J.L. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol. 2008;43(2):142–149.
    1. Lee N., Wong C.K., Chan M.C.W., Yeung E.S.L., Tam W.W.S., Tsang O.T.Y. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antiviral Res. 2017;144:48–56.
    1. Lendermon E.A., Coon T.A., Bednash J.S., Weathington N.M., McDyer J.F., Mallampalli R.K. Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. Respir Res. 2017;18(1):131.
    1. Martin-Loeches I., Bermejo-Martin J.F., Valles J., Granada R., Vidaur L., Vergara-Serrano J.C. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med. 2013;39(4):693–702.
    1. McCallum G.B., Morris P.S., Chatfield M.D., Maclennan C., White A.V., Sloots T.P. A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial. PLoS One. 2013;8(9)
    1. Min J.Y., Jang Y.J. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012
    1. Mosquera R.A., Stark J.M., Atkins C.L., Colasurdo G.N., Chevalier J., Samuels C.L. Functional and immune response to respiratory syncytial virus infection in aged BALB/c mice: a search for genes determining disease severity. Exp Lung Res. 2014;40(1):40–49.
    1. Nakamura H., Fujishima S., Inoue T., Ohkubo Y., Soejima K., Waki Y. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999;13(6):1371–1379.
    1. NIH. Macrolide antibiotics; 2017. Available from: . [Accessed 1 November 2018].
    1. Ninomiya K., Fukui T., Imai T., Matsui M., Matsuoka K. Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza. J Nippon Med Sch = Nippon Ika Daigaku zasshi. 2002;69(1):53–57.
    1. Pinto L.A., Pitrez P.M., Luisi F., de Mello P.P., Gerhardt M., Ferlini R. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. J Pediatr. 2012;161(6):1104–1108.
    1. Schogler A., Kopf B.S., Edwards M.R., Johnston S.L., Casaulta C., Kieninger E. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015;45(2):428–439.
    1. Shinahara W., Takahashi E., Sawabuchi T., Arai M., Hirotsu N., Takasaki Y. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013;8(7)
    1. Suzuki T., Yamaya M., Sekizawa K., Hosoda M., Yamada N., Ishizuka S. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med. 2002;165(8):1113–1118.
    1. Tahan F., Ozcan A., Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2007;29(1):91–97.
    1. Us D. Cytokine storm in avian influenza. Mikrobiyol Bul. 2008;42(2):365–380.
    1. Vincent J.L., de Mendonca A., Cantraine F., Moreno R., Takala J., Suter P.M. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793–1800.
    1. Wales D., Woodhead M. The anti-inflammatory effects of macrolides. Thorax. 1999;54(Suppl. 2):S58–62.
    1. Walkey A.J., Wiener R.S. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012;141(5):1153–1159.
    1. Wang J., Nikrad M.P., Travanty E.A., Zhou B., Phang T., Gao B. Innate immune response of human alveolar macrophages during influenza A infection. PLoS One. 2012;7(3)
    1. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68(5):479–503.
    1. Zhang C., Xu Y., Jia L., Yang Y., Wang Y., Sun Y. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010;7:30.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner